This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Alexion Pharmaceuticals, Inc.
Drug Names(s): 5G1.1-SC
Description: Pexelizumab is a monoclonal antibody fragment that targets the C5 component of complement, an important component of the innate immune system.
Deal Structure: In January 1999, Alexion and Procter & Gamble partnered to develop and commercialize pexelizumab. In December 2001, the agreement was updated so that Alexion and P & G would share U.S. development and commercialization costs for pexelizumab.
In January 1999, Alexion entered into a collaboration with P&G with respect to the joint development of pexelizumab. In December 2001, Alexion and P&G entered into a binding memorandum of understanding, or MOU, pursuant to which Alexion and P&G revised the January 1999 collaboration. Under the revised structure per the MOU, Alexion and P&G will share decision-making and responsibility for all future U.S. development and commercialization costs for pexelizumab, including clinical, manufacturing, marketing, and sales efforts. Prior to December 2001, P&G was generally funding all clinical development and manufacturing costs for pexelizumab. The revised collaboration per the MOU provides that Alexion and P&G each incur approximately 50% of all...See full deal structure in Biomedtracker
Partners: PDL BioPharma, Inc.
Pink Sheet Alexion pexelizumab fails second PRIMO study
Additional information available to subscribers only: